Skip to main content Accessibility help
×
Home

Recurrent head and neck cancer: United Kingdom National Multidisciplinary Guidelines

  • H Mehanna (a1), A Kong (a2) and SK Ahmed (a3)

Abstract

This is the official guideline endorsed by the specialty associations involved in the care of head and neck cancer patients in the UK. Recurrent cancers present some of the most challenging management issues in head and neck surgical and oncological practice. This is rendered even more complex by the poor evidence base to support management options, the substantial implications that treatments can have on the function and quality of life, and the difficult decision-making considerations for supportive care alone. This paper provides consensus recommendations on the management of recurrent head and neck cancer.

Recommendations

• Consider baseline and serial scanning with computed tomography and/or magnetic resonance (CT and/or MR) to detect recurrence in high-risk patients. (R)

• Patients with head and neck cancer recurrence being considered for active curative treatment should undergo assessment by positron emission tomography combined with computed tomography (PET–CT) scan. (R)

• Patients with recurrence should be assessed systematically by a team experienced in the range of management options available for recurrence including surgical salvage, re-irradiation, chemotherapy and palliative care. (R)

• Management of patients with laryngeal recurrence should include input from surgeons with experience in transoral surgery and partial laryngectomy for recurrence. (G)

• Expertise in transoral surgery and partial laryngectomy for recurrence should be concentrated to a few surgeons within each multidisciplinary teams. (G)

• Transoral or open partial laryngectomy should be offered as definitive treatment modality for highly-selected patients with recurrent laryngeal cancer. (R)

• Patients with OPC recurrence should have p16 human papilloma virus status assessed. (R)

• Patients with OPC recurrence should be considered for salvage surgical treatment by an experienced team, with reconstructive expertise input. (G)

• Transoral surgery appears to be an effective alternative to open surgery for the management of OPC recurrence in carefully selected patients. (R)

• Consider elective selective neck dissections in patients with recurrent primaries with N0 necks, especially in advanced cases. (R)

• Selective neck dissection (with preservation of nodal levels, especially level V, that are not involved by disease) in patients with nodal (N+) recurrence appears to be as effective as modified or radical neck dissections. (R)

• Use salivary bypass tubes following salvage laryngectomy. (R)

• Use interposition muscle-only pectoralis major or free flap for suture line reinforcement if performing primary closure following salvage laryngectomy. (R)

• Use inlaid pedicled or free flap to close wound if there is tension at the anastomosis following laryngectomy. (R)

• Perform secondary puncture in post chemoradiotherapy laryngectomy patients. (R)

• Triple therapy with platinum, cetuximab and 5-fluorouracil (5-FU) appears to provide the best outcomes for the management of patients with recurrence who have a good performance status and are fit to receive it. If not fit, then combinations of platinum and cetuximab or platinum and 5-FU may be considered. (R)

• Patients with non-resectable recurrent disease should be offered the opportunity to participate in phases I–III clinical trials of new therapeutic agents. (R)

• Chemo re-irradiation appears to improve locoregional control, and may have some benefit for overall survival, at the risk of considerable acute and late toxicity. Benefit must be weighed carefully against risks, and patients must be counselled appropriately. (R)

• Target volumes should be kept tight and elective nodal irradiation should be avoided. (R)

• Best supportive care should be offered routinely as part of the management package of all patients with recurrent cancer even in the case of those who are being treated curatively. (R)

  • View HTML
    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Recurrent head and neck cancer: United Kingdom National Multidisciplinary Guidelines
      Available formats
      ×

      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Recurrent head and neck cancer: United Kingdom National Multidisciplinary Guidelines
      Available formats
      ×

      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Recurrent head and neck cancer: United Kingdom National Multidisciplinary Guidelines
      Available formats
      ×

Copyright

This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.

Corresponding author

Address for correspondence: Prof Hisham Mehanna, Institute of Head and Neck Studies and Education, College of Medical and Dental Sciences, University of Birmingham, Edgbaston, Birmingham, UK E-mail: h.mehanna@bham.ac.uk

References

Hide All
1 Weber, RS, Berkey, BA, Forastiere, A, Cooper, J, Maor, M, Goepfert, H et al. Outcome of salvage total laryngectomy following organ preservation therapy: the radiation therapy oncology group trial 91–11. Arch Otolaryngol Head Neck Surg 2003;129:44–9
2 Jayaram, SC, Muzaffar, SJ, Ahmed, I, Dhanda, J, Paleri, V, Mehanna, HM. The efficacy, outcomes and complication rates of different surgical and nonsurgical treatment modalities for recurrent/residual oropharyngeal carcinoma: a systematic review and meta-analysis. Head Neck 2016 [in press]
3 Mehanna, H, Ang, KK. Management of Recurrence in Head and Neck Cancer. USA: Thieme Medical Publishers, 2012
4 Fakhry, C, Zhang, Q, Nguyen-Tan, PF, Rosenthal, D, El-Naggar, A, Garden, AS et al. Human papillomavirus and overall survival after progression of oropharyngeal squamous cell carcinoma. J Clin Oncol 2014;32:3365–73
5 Gupta, T, Master, Z, Kannan, S, Agarwal, JP, Ghsoh-Laskar, S, Rangarajan, V et al. Diagnostic performance of post-treatment FDG PET or FDG PET/CT imaging in head and neck cancer: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging 2011;38:2083–95
6 Gao, S, Li, S, Yang, X, Tang, Q. 18FDG PET-CT for distant metastases in patients with recurrent head and neck cancer after definitive treatment. A meta-analysis. Oral Oncol 2014;50:163–7
7 Dunsky, KA, Wehrmann, DJ, Osman, MM, Thornberry, BM, Varvares, MA. PET-CT and the detection of the asymptomatic recurrence or second primary lesions in the treated head and neck cancer patient. Laryngoscope 2013;123:2161–4
8 Zafereo, ME, Hanasono, MM, Rosenthal, DI, Sturgis, EM, Lewin, JS, Roberts, DB et al. The role of salvage surgery in patients with recurrent squamous cell carcinoma of the oropharynx. Cancer 2009;115:5723–33
9 Paleri, V, Kelly, CG. Re-irradiation with concurrent chemotherapy in recurrent head and neck cancer: a decision analysis model based on a systematic review. Clin Otolaryngol 2008;33:331–7
10 Steiner, W, Vogt, P, Ambrosch, P, Kron, M. Transoral carbon dioxide laser microsurgery for recurrent glottic carcinoma after radiotherapy. Head Neck 2004;26:477–84
11 Roedel, RM, Matthias, C, Wolff, HA, Christiansen, H. Repeated transoral laser microsurgery for early and advanced recurrence of early glottic cancer after primary laser resection. Auris Nasus Larynx 2010;37:340–6
12 Ramakrishnan, Y, Drinnan, M, Kwong, FN, Grant, DG, Mehana, H, Jones, T et al. Oncologic outcomes of transoral laser microsurgery for radiorecurrent laryngeal carcinoma: a systematic review and meta-analysis of English-language literature. Head Neck 2014;36:280–5
13 Paleri, V, Drinnan, M, van den Brekel, MW, Hinni, MW, Bradley, ML, Wolf, PJ et al. Vascularized tissue to reduce fistula following salvage total laryngectomy: a systematic review. Laryngoscope 2014;124:1848–53
14 Marioni, G, Marchese-Ragona, R, Pastore, A, Staffieri, A. The role of supracricoid laryngectomy for glottic carcinoma recurrence after radiotherapy failure: a critical review. Acta Otolaryngol 2006;126:1245–51
15 White, H, Ford, S, Bush, B, Holsinger, FC, Moore, E, Ghanem, T et al. Salvage surgery for recurrent cancers of the oropharynx: comparing TORS with standard open surgical approaches. JAMA Otolaryngol Head Neck Surg 2013;139:773–8
16 Paydarfar, JA, Birkmeyer, NJ. Complications in head and neck surgery: a meta-analysis of postlaryngectomy pharyngocutaneous fistula. Arch Otolaryngol Head Neck Surg 2006;132:6772
17 Pezier, TF, Nixon, IJ, Scotton, W, Joshi, A, Guerrero-Urbano, T, Oakley, R et al. Should elective neck dissection be routinely performed in patients undergoing salvage total laryngectomy? J Laryngol Otol 2014;128:279–83
18 van der Putten, L, van den Broek, GB, de Bree, R, van den Brekel, MWM, Balm, AJM, Hoebers, FJP et al. Effectiveness of salvage selective and modified radical neck dissection for regional pathologic lymphadenopathy after chemoradiation. Head Neck 2009;31:593603
19 Robbins, KT, Doweck, I, Samant, S, Vieira, F. Effectiveness of superselective and selective neck dissection for advanced nodal metastases after chemoradiation. Arch Otolaryngol Head Neck Surg 2005;131:965–9
20 Murray, DJ, Gilbert, RW, Vesely, MJ, Novak, CB, Zaitlin-Gencher, S, Clark, JR et al. Functional outcomes and donor site morbidity following circumferential pharyngoesophageal reconstruction using an anterolateral thigh flap and salivary bypass tube. Head Neck 2007;29:147–54
21 Vermorken, JB, Remenar, E, van Herpen, C, Gorlia, T, Mesia, R, Degardin, M et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 2007;357:1695–704
22 Burtness, B, Goldwasser, MA, Flood, W, Mattar, B, Forastiere, AA, Eastern Cooperative Oncology G. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol 2005;23:8646–54
23 Vermorken, JB, Mesia, R, Rivera, F, Remenar, E, Kawecki, A, Rottey, S et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008;359:1116–27
24 Tanvetyanon, T, Padhya, T, McCaffrey, J, Zhu, W, Boulware, D, DeConti, R et al. Prognostic factors for survival after salvage reirradiation of head and neck cancer. J Clin Oncol 2009;27:1983–91
25 Spencer, SA, Harris, J, Wheeler, RH, Machtay, M, Schultz, C, Spanos, W et al. Final report of RTOG 9610, a multi-institutional trial of reirradiation and chemotherapy for unresectable recurrent squamous cell carcinoma of the head and neck. Head Neck 2008;30:281–8
26 Tortochaux, J, Tao, Y, Tournay, E, Lapeyre, M, Lesaunier, F, Bardet, E et al. Randomized phase III trial (GORTEC 98–03) comparing re-irradiation plus chemotherapy versus methotrexate in patients with recurrent or a second primary head and neck squamous cell carcinoma, treated with a palliative intent. Radiother Oncol 2011;100:70–5
Type Description Title
PDF
Full supplement PDF

Full supplement PDF
Full supplement PDF

 PDF (10.5 MB)
10.5 MB

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed